MVRBF News and Press, Medivir B From 02/13/20

Medivir AB ( OTC:MVRBF ): Q4 GAAP EPS of -SEK1.32. Revenue of SEK1.4M (-89.7% Y/Y) Press Release More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, ,

HUDDINGE, Sweden , Feb. 13, 2020 /PRNewswire/ -- October - December Significant events during the quarter             Preclinical data showing that in addition to its direct effect on cancer cells, MIV-818 also modulates the ...

STOCKHOLM , Feb. 11, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to an R&D Day in Stockholm , Monday March 2, 2020 , at 14:00 to 16:30 CET . The presentations will, among other things, address new clinical results from...

STOCKHOLM , Jan. 20, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal Annals of Internal Medicine ( DOI: 10.7326/M19-0675). The title of the article is ...

STOCKHOLM , Dec. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC). Th...

Medivir AB ( OTC:MVRBF ): Q3 GAAP EPS of -SEK0.95. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...

STOCKHOLM , Nov. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase Ia study of MIV-818 in patients with advanced liver cancer. Based on data from phase Ia, the initial dose of MIV-818 for the phase...

STOCKHOLM , Oct. 30, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that a poster entitled "MIV-818 stimulates an anti-tumor immune response in vitro and enhances the effects of pembrolizumab" was presented at the AACR-NCI-EORTC conference in Boston . The...

STOCKHOLM , Oct. 10, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR)  today announces that the first patient has been enrolled in a phase I study to investigate the safety and tolerability of a combination treatment of birinapant and radiation therapy in patients with recur...

Medivir AB ( OTC:MVRBF ): Q2 GAAP EPS of -SEK0.51. More news on: Medivir AB (publ), Medivir AB ADR, Earnings news and commentary, Tech stocks news, , Read more ...